Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1557-1561

  Kwon, Hyuk Chan ^a   Kim, Sung Hyun ^a   Oh, Sung Yong ^a   Lee, Suee ^a   Kwon, Kyung A ^a   Lee, Jong Hoon ^a   Choi, Hong Jo ^a   Park, Ki Jae ^a   Lee, Hyung Sik ^a   Roh, Mee Sook ^a   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NF-KAPPA B; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954157682     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01553.x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-49.
2. Jung KW, Yim SH, Kong HJ. Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci 2007, 22(Suppl):S5-10.
3. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 2008, 147:99-107.
4. Kuwai T, Kitadai Y, Tanaka S. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003, 105:176-81.
5. Furlan D, Sahnane N, Carnevali I. Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg Oncol 2007, 16(Suppl 1):S25-7.
6. Yoshimura H, Dhar DK, Kohno H. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004, 10:8554-60.
7. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72.
8. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995, 92:5510-4.
9. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
10. Chai CY, Chen WT, Hung WC. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 2008, 61:658-64.
11. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-8.
12. Sakamoto K, Maeda S, Hikiba Y. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009, 15:2248-58.
13. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008, 412:477-84.
14. Yu HG, Zhong X, Yang YN. Increased expression of nuclear factor-kappaB/RelA is correlated with tumor angiogenesis in human colorectal cancer. Int J Colorectal Dis 2004, 19:18-22.
15. Hsu FD, Nielsen TO, Alkushi A. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002, 15:1374-80.
16. Westra JL, Schaapveld M, Hollema H. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005, 23:5635-43.
17. Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis 2007, 22:863-8.
18. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007, 13:5670-4.
19. Zhong H, De Marzo AM, Laughner E. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5.
20. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009, 107:1053-62.
21. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001, 7:1661-8.
22. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001, 19:1207-25.
23. Zheng S, Han MY, Xiao ZX, Peng JP, Dong Q. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003, 9:1227-30.
24. Belaiba RS, Bonello S, Zahringer C. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007, 18:4691-7.
25. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5:412-7.